Fortress - FBIO Net Assets per Single Share

The historical book value per share for Fortress Biotech, Inc. (FBIO), where the value is maintained at 4.93, confirms the strategy of monetizing FDA-approved drugs to support new research. The incubator's diversified approach minimizes risks associated with individual product failures. Meanwhile, management is effectively scaling the holding's value by creating and taking promising biotech subsidiaries public.

Fortress Biotech Inc (FBIO) - Accounting Value per Share from 07/04/2022 to 10/27/2026

Summary analytical data breakdowns for fortressbiotech.com (FBIO)

- price and consensus price forecast:

Stock Price Fortress|FBIO - Analyst Median Target

- market capitalization data:

Market Value Fortress Biotech, Inc.|FBIO - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Fortress Biotech|FBIO - Company Net Assets|Market Capitalization to Book Value Ratio fortressbiotech.com|FBIO - Company Total Asset Base

- debt and liquidity data:

Debt to Equity Fortress Biotech, Inc.|FBIO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Fortress Biotech|FBIO - Company Total Debt|Debts to Book Capitalization Fortress Biotech, Inc.

Analysis of all company metrics:Fortress, FBIO

Book value per share is calculated as the difference between a company's total assets and liabilities divided by the number of outstanding shares, which determines the actual value of capital for the shareholder. For the Fortress Biotech, Inc. (FBIO) holding structure under the leadership of Lindsay Rosenwald, this metric reflects the efficiency of managing subsidiary assets and securing external financing, as clearly captured by the current book value per share.

Competitor analysis for Fortress Biotech, Inc.

Book Value per Share NVCR (NovoCure Corp)|DRTS: Net Assets per Share|Net Assets per Single Share ACRV|ALLR (Allarity Therapeutics, Inc.) - Net Asset Value per Share